{"title":"弥散性癌患者的血管内动脉瘤修复:ACS-NSQIP数据库2012-2022年倾向评分匹配研究","authors":"Renxi Li, Anton Sidawy, Bao-Ngoc Nguyen","doi":"10.1177/17085381251360087","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundDisseminated cancer may complicate decision-making processes for major surgical interventions, including endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA). However, the postoperative outcomes of EVAR in patients with disseminated cancer have not been well-established. This study aimed to explore the impact of preoperative disseminated cancer on 30-day outcomes of non-ruptured EVAR.MethodsPatients who underwent infrarenal EVAR were identified in ACS-NSQIP targeted database from 2012 to 2022. Exclusion criteria included age <18 years, ruptured aneurysm, acute intraoperative conversion to open repair, and emergency cases. A 1:3 propensity-score matching was used to match demographics, baseline characteristics, aneurysm diameter, distant aneurysm extent, anesthesia, and concomitant procedures between patients with and without preoperative disseminated cancer. Thirty-day postoperative EVAR outcomes were examined.ResultsThere were 154 (0.80%) patients with disseminated cancer who underwent non-ruptured EVAR. Meanwhile, 19,109 patients without disseminated cancer went under EVAR, where 462 of them were matched to all patients with disseminated cancer. After propensity-score matching, patients with and without disseminated cancer had comparable mortality rates (5.19% vs 4.76%, <i>p</i> = 0.83). However, patients with disseminated cancer had higher lower extremity ischemia (2.60% vs 0.43%, <i>p</i> = 0.04), unplanned reoperation (9.74% vs 3.90%, <i>p</i> = 0.01), and 30-day readmission (19.48% vs 10.61%, <i>p</i> = 0.01).ConclusionDisseminated cancer is significantly more prevalent among patients undergoing EVAR than the general population (0.05%), likely due to shared pathophysiology between AAA development and the incidence and progression of cancer. While EVAR is relatively safe in terms of short-term outcomes in patients with disseminated cancer, the long-term prognosis for these patients needs further investigation.</p>","PeriodicalId":23549,"journal":{"name":"Vascular","volume":" ","pages":"17085381251360087"},"PeriodicalIF":0.9000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Endovascular aneurysm repair for patients with disseminated cancer: A propensity-score matched study from ACS-NSQIP database from 2012-2022.\",\"authors\":\"Renxi Li, Anton Sidawy, Bao-Ngoc Nguyen\",\"doi\":\"10.1177/17085381251360087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BackgroundDisseminated cancer may complicate decision-making processes for major surgical interventions, including endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA). However, the postoperative outcomes of EVAR in patients with disseminated cancer have not been well-established. This study aimed to explore the impact of preoperative disseminated cancer on 30-day outcomes of non-ruptured EVAR.MethodsPatients who underwent infrarenal EVAR were identified in ACS-NSQIP targeted database from 2012 to 2022. Exclusion criteria included age <18 years, ruptured aneurysm, acute intraoperative conversion to open repair, and emergency cases. A 1:3 propensity-score matching was used to match demographics, baseline characteristics, aneurysm diameter, distant aneurysm extent, anesthesia, and concomitant procedures between patients with and without preoperative disseminated cancer. Thirty-day postoperative EVAR outcomes were examined.ResultsThere were 154 (0.80%) patients with disseminated cancer who underwent non-ruptured EVAR. Meanwhile, 19,109 patients without disseminated cancer went under EVAR, where 462 of them were matched to all patients with disseminated cancer. After propensity-score matching, patients with and without disseminated cancer had comparable mortality rates (5.19% vs 4.76%, <i>p</i> = 0.83). However, patients with disseminated cancer had higher lower extremity ischemia (2.60% vs 0.43%, <i>p</i> = 0.04), unplanned reoperation (9.74% vs 3.90%, <i>p</i> = 0.01), and 30-day readmission (19.48% vs 10.61%, <i>p</i> = 0.01).ConclusionDisseminated cancer is significantly more prevalent among patients undergoing EVAR than the general population (0.05%), likely due to shared pathophysiology between AAA development and the incidence and progression of cancer. While EVAR is relatively safe in terms of short-term outcomes in patients with disseminated cancer, the long-term prognosis for these patients needs further investigation.</p>\",\"PeriodicalId\":23549,\"journal\":{\"name\":\"Vascular\",\"volume\":\" \",\"pages\":\"17085381251360087\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17085381251360087\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17085381251360087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
摘要
播散性癌症可能使重大手术干预的决策过程复杂化,包括腹主动脉瘤(AAA)的血管内动脉瘤修复(EVAR)。然而,播散性癌症患者的EVAR术后结果尚未确定。本研究旨在探讨术前弥散性肿瘤对未破裂EVAR患者30天预后的影响。方法选取2012 - 2022年ACS-NSQIP目标数据库中接受肾下EVAR的患者。排除标准包括年龄p = 0.83)。而弥散性癌患者下肢缺血发生率较高(2.60% vs 0.43%, p = 0.04),非计划再手术发生率较高(9.74% vs 3.90%, p = 0.01), 30天再入院率较高(19.48% vs 10.61%, p = 0.01)。结论弥散性癌在EVAR患者中的发生率明显高于普通人群(0.05%),这可能是由于AAA的发生与癌症的发生和进展之间存在共同的病理生理机制。虽然就播散性癌症患者的短期预后而言,EVAR是相对安全的,但这些患者的长期预后需要进一步研究。
Endovascular aneurysm repair for patients with disseminated cancer: A propensity-score matched study from ACS-NSQIP database from 2012-2022.
BackgroundDisseminated cancer may complicate decision-making processes for major surgical interventions, including endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA). However, the postoperative outcomes of EVAR in patients with disseminated cancer have not been well-established. This study aimed to explore the impact of preoperative disseminated cancer on 30-day outcomes of non-ruptured EVAR.MethodsPatients who underwent infrarenal EVAR were identified in ACS-NSQIP targeted database from 2012 to 2022. Exclusion criteria included age <18 years, ruptured aneurysm, acute intraoperative conversion to open repair, and emergency cases. A 1:3 propensity-score matching was used to match demographics, baseline characteristics, aneurysm diameter, distant aneurysm extent, anesthesia, and concomitant procedures between patients with and without preoperative disseminated cancer. Thirty-day postoperative EVAR outcomes were examined.ResultsThere were 154 (0.80%) patients with disseminated cancer who underwent non-ruptured EVAR. Meanwhile, 19,109 patients without disseminated cancer went under EVAR, where 462 of them were matched to all patients with disseminated cancer. After propensity-score matching, patients with and without disseminated cancer had comparable mortality rates (5.19% vs 4.76%, p = 0.83). However, patients with disseminated cancer had higher lower extremity ischemia (2.60% vs 0.43%, p = 0.04), unplanned reoperation (9.74% vs 3.90%, p = 0.01), and 30-day readmission (19.48% vs 10.61%, p = 0.01).ConclusionDisseminated cancer is significantly more prevalent among patients undergoing EVAR than the general population (0.05%), likely due to shared pathophysiology between AAA development and the incidence and progression of cancer. While EVAR is relatively safe in terms of short-term outcomes in patients with disseminated cancer, the long-term prognosis for these patients needs further investigation.
期刊介绍:
Vascular provides readers with new and unusual up-to-date articles and case reports focusing on vascular and endovascular topics. It is a highly international forum for the discussion and debate of all aspects of this distinct surgical specialty. It also features opinion pieces, literature reviews and controversial issues presented from various points of view.